Abstract
The pharmaceutical services firms Famar and Delpharm confirm that they are in talks about the sale of five Famar finished-drug manufacturing plants to Delpharm. The sites—three in France, one in the Netherlands, and one in Canada—have combined annual sales of about $275 million and a total of 1,300 employees. Delpharm currently operates at 12 sites in France, Belgium, and Italy. Famar’s parent company, the supermarket giant Marinopoulos, faced bankruptcy during Greece’s economic crisis in 2016. Famar produces finished drugs at six other sites in Europe.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
